Neurocrine Biosciences Inc (NBIX) Company Report Oct. 27, 2022, 06:44 UTC Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-1117568 in Adults with Schizophrenia Full text
There are no comments here yet...